| Product Name | EPO ELISA kit (Human) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Erythropoietin (EPO). No significant cross-reactivity or interference between Erythropoietin (EPO) and analogues was observed. |
| Synonyms | EP; Epoetin; Erythropoetin; Hematopoietin; Hemopoietin |
| Method | Sandwich |
| Detection Range | 31.2-2,000pg/mL |
| Sensitivity | 12.1pg/mL |
| Target | EPO |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Erythropoietin (EPO). No significant cross-reactivity or interference between Erythropoietin (EPO) and analogues was observed. |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 100uL standard or sample to each well.Incubate 2 hours at 37℃; 3.Aspirate and add 100uL prepared Detection Reagent A.Incubate 1 hour at 37℃; 4.Aspirate and wash 3 times; 5.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 6.Aspirate and wash 5 times; 7.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 8.Add 50uL Stop Solution.Read at 450nm immediately. |
| Uniprot | P01588 |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | CD98 Positive Eosinophils Contribute to T Helper 1 Pattern Inflammation;Alterations of Circulating Endothelial Cell and Endothelial Progenitor Cell Counts around the Ovulation;Carbohydrate and glutamine supplementation modulates the Th1/Th2 balance after exercise performed at a simulated altitude of 4500 m.;Decreased plasma soluble erythropoietin receptor in high-altitude excessive erythrocytosis and Chronic Mountain Sickness;Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone;KIAA0101 is associated with human renal cell carcinoma proliferation and migration induced by erythropoietin;Expression of Iron-Related Proteins Differentiate Non-Cancerous and Cancerous Breast Tumors.;Acidic Polysaccharide from Angelica sinensis Reverses Anemia of Chronic Disease Involving the Suppression of Inflammatory Hepcidin and NF-κB Activation;Functional and phenotypic evaluation of eosinophils from patients with the acute form of paracoccidioidomycosis;Study of acute hypoxia markers in healthy subjects: Utility in post-crash investigation;Effects of erythropoietin on astrocytes and brain endothelial cells in primary culture during anoxia depend on simultaneous signaling by other cytokines and on …;Increased NGAL level associated with iron store in chronic kidney disease with anemia;High-altitude hypoxia decreases plasma erythropoietin soluble receptor (sEpoR) concentration in humans;PHYSIOLOGICAL ADAPTATIONS TO HEAT ACCLIMATION; REPERCUSSIONS ON CYCLING PERFORMANCE;Effects of carbohydrate and glutamine supplementation on cytokine production by monocytes after exercise in hypoxia: a crossover, randomized and double-blind …;Disordered serum erythroferrone and hepcidin levels as indicators of the spontaneous abortion occurrence during early pregnancy in humans;Increased FGF-23 levels are linked to ineffective erythropoiesis and impaired bone mineralization in myelodysplastic syndromes;EPAS1 regulates proliferation of erythroblasts in chronic mountain sickness;miR663 Prevents Epo Inhibition Caused by TNF-Alpha in Normoxia and Hypoxia;Loading of erythropoietin on biphasic calcium phosphate bioceramics promotes osteogenesis and angiogenesis by regulating EphB4/EphrinB2 molecules; |
| Supplier | Cloud Clone |
PROTOCOLS:
SEA028Hu All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
